Literature DB >> 10921943

Detection of complement-mediated antibody-dependent bactericidal activity in a fluorescence-based serum bactericidal assay for group B Neisseria meningitidis.

K T Mountzouros1, A P Howell.   

Abstract

Serum bactericidal assays (SBAs) for Group B meningococci are considered the methods of choice for the evaluation of functional antimeningococcal antibodies. Many investigators regard SBAs as time- and labor-intensive. Variations in SBA protocols among different laboratories make interpretation of results difficult. Here we describe a fluorescence-based serum bactericidal assay (fSBA) and compare the results obtained with the fSBA to the results obtained with a more conventional SBA. The results generated by both assays were dependent upon the surviving bacteria after incubation, and the assay mixtures contained identical components. Differences between assays lie in how the surviving bacteria are quantified. The fSBA described in the paper uses the fluorescent dye alamarBlue (M. V. Lancaster and R. D. Fields, U.S. patent 5501959, March 1996). The fluorescent signals generated in the fSBA correlate to the oxidative respiration of surviving bacteria. Viable bacteria were detected between 6 and 8 h directly from reaction mixtures in 96-well plates by the fSBA, whereas colonies isolated on semisolid media could be counted after 24 h of incubation. The bactericidal titers generated by both assays were nearly identical. The fSBA described here can be used as an assay for the screening of large quantities of individual sera as complement sources or as a method for the detection of functional antibodies directed against group B Neisseria meningitidis in both human and mouse antisera.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10921943      PMCID: PMC87135     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  37 in total

1.  Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.

Authors:  S E Maslanka; L L Gheesling; D E Libutti; K B Donaldson; H S Harakeh; J K Dykes; F F Arhin; S J Devi; C E Frasch; J C Huang; P Kriz-Kuzemenska; R D Lemmon; M Lorange; C C Peeters; S Quataert; J Y Tai; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

2.  Classification of Neisseria meningitidis group B into distinct serotypes. I. Serological typing by a microbactericidal method.

Authors:  C E Frasch; S S Chapman
Journal:  Infect Immun       Date:  1972-01       Impact factor: 3.441

3.  Human antibody responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine: results from ELISA studies.

Authors:  E Rosenqvist; E A Høiby; G Bjune; K Bryn; O Closs; B Feiring; A Klem; H Nøkleby; L O Frølm
Journal:  NIPH Ann       Date:  1991-12

4.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.

Authors:  E Rosenqvist; E A Høiby; E Wedege; K Bryn; J Kolberg; A Klem; E Rønnild; G Bjune; H Nøkleby
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

5.  Quantitation of IgG subclass antibody responses after immunization with a group B meningococcal outer membrane vesicle vaccine, using monoclonal mouse-human chimeric antibodies as standards.

Authors:  L M Naess; E Rosenqvist; E A Høiby; T E Michaelsen
Journal:  J Immunol Methods       Date:  1996-09-13       Impact factor: 2.303

6.  Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection.

Authors:  E Rosenqvist; S Harthug; L O Frøholm; E A Høiby; K Bøvre; W D Zollinger
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

7.  NEISSERIA GONORRHOEAE. I. VIRULENCE GENETICALLY LINKED TO CLONAL VARIATION.

Authors:  D S KELLOGG; W L PEACOCK; W E DEACON; L BROWN; D I PIRKLE
Journal:  J Bacteriol       Date:  1963-06       Impact factor: 3.490

8.  Humoral immune responses to Neisseria meningitidis in children.

Authors:  A J Pollard; R Galassini; E M van der Voort; R Booy; P Langford; S Nadel; C Ison; J S Kroll; J Poolman; M Levin
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

9.  Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.

Authors:  C E Frasch; J D Robbins
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  14 in total

1.  Opsonophagocytosis of fluorescent polystyrene beads coupled to Neisseria meningitidis serogroup A, C, Y, or W135 polysaccharide correlates with serum bactericidal activity.

Authors:  Joseph Martinez; Tamara Pilishvili; Suzanne Barnard; Joseph Caba; Willie Spear; Sandra Romero-Steiner; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

2.  Measurement of serum bactericidal activity specific for Haemophilus influenzae type b by using a chromogenic and fluorescent metabolic indicator.

Authors:  Sandra Romero-Steiner; Willie Spear; Nekeidra Brown; Patricia Holder; Thomas Hennessy; Patricia Gomez De Leon; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

3.  Fluorescent multivalent opsonophagocytic assay for measurement of functional antibodies to Streptococcus pneumoniae.

Authors:  Kathryn T Bieging; Gowrisankar Rajam; Patricia Holder; Ross Udoff; George M Carlone; Sandra Romero-Steiner
Journal:  Clin Diagn Lab Immunol       Date:  2005-10

4.  Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model.

Authors:  Duzhang Zhu; Ying Zhang; Vicki Barniak; Liesel Bernfield; Alan Howell; Gary Zlotnick
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

5.  A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model.

Authors:  Kenneth T Mountzouros; Kelly A Belanger; Alan P Howell; Garvin S Bixler; Dace V Madore
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

6.  Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis.

Authors:  Puiying A Mak; George F Santos; Kelly-Anne Masterman; Jeff Janes; Bill Wacknov; Kay Vienken; Marzia Giuliani; Ann E Herman; Michael Cooke; M Lamine Mbow; John Donnelly
Journal:  Clin Vaccine Immunol       Date:  2011-06-29

7.  Standardization of Neisseria meningitidis serogroup B colorimetric serum bactericidal assay.

Authors:  Tamara Rodríguez; Miriam Lastre; Barbara Cedré; Judith del Campo; Gustavo Bracho; Caridad Zayas; Carlos Taboada; Miriam Díaz; Gustavo Sierra; Oliver Pérez
Journal:  Clin Diagn Lab Immunol       Date:  2002-01

8.  Detecting bacteria and determining their susceptibility to antibiotics by stochastic confinement in nanoliter droplets using plug-based microfluidics.

Authors:  James Q Boedicker; Liang Li; Timothy R Kline; Rustem F Ismagilov
Journal:  Lab Chip       Date:  2008-07-04       Impact factor: 6.799

9.  Vaccine potential of the Neisseria meningitidis 2086 lipoprotein.

Authors:  Leah D Fletcher; Liesel Bernfield; Vicki Barniak; John E Farley; Alan Howell; Melissa Knauf; Peggy Ooi; Robert P Smith; Paige Weise; Mike Wetherell; Xiaoling Xie; Robert Zagursky; Ying Zhang; Gary W Zlotnick
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

10.  A Novel Luminescence-Based Serum Bactericidal Assay for Vibrio cholerae Reduces Assay Variation, Is Time- and Cost-Effective, and Directly Measures Continuous Titer Values.

Authors:  Taylor A Wahlig; Ben J Brintz; Melanie Prettyman; Andrew S Azman; Daniel T Leung
Journal:  Am J Trop Med Hyg       Date:  2021-07-08       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.